Barclays raised the firm’s price target on Regeneron to $925 from $900 and keeps an Overweight rating on the shares. The FDA approval Eylea HD and the pricing is a tad higher than expectations, the analyst tells investors in a research note. The firm says the approval sets the stage for the U.S. Eylea franchise return to growth in 2024, benefiting from J-code and loading dose dynamics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Regeneron Stock (NASDAQ:REGN): Analysts are Bullish Post FDA Approval
- EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
- RBC says Regeneron news intimates high-dose Eylea approval likely
- Regeneron announces FDA approval of Veopoz for Chaple disease
- Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease